To determine if IGFBP2 has any biologic consequences in LAM patient-derived TSC2-null cells, IGFBP2 was knocked down by siRNA transfection in LAM patient-derived cells (Figure 4B). Here, IGFBP2 is linked to lymphangioleiomyomatosis.